<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04563000</url>
  </required_header>
  <id_info>
    <org_study_id>VitC</org_study_id>
    <nct_id>NCT04563000</nct_id>
  </id_info>
  <brief_title>Impact of Vitamin C on Biomarkers of Neurologic Injury in Survivors of Cardiac Arrest</brief_title>
  <official_title>Impact of Vitamin C on Biomarkers of Neurologic Injury in Patients With Return of Spontaneous Circulation After Out-of-Hospital Cardiac Arrest</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Centre Maribor</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Centre Maribor</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Out-of-hospital cardiac arrest (OHCA) is one of the leading cause of death in the world. In&#xD;
      Slovenia approximately 25% of resuscitated patients survives to discharge from hospitals,&#xD;
      usually with poorer functional status.&#xD;
&#xD;
      One of key pathophysiological process responsible for poorer functional status is global&#xD;
      hypoxic-ischemic injury, which is two-stage. Primary stage occurs immediately after cardiac&#xD;
      arrest due to cessation of blood flow. With return of spontaneous circulation a secondary&#xD;
      injury occurs, of which the leading process is an imbalance between oxygen delivery and&#xD;
      consumption. Reperfusion exposes ischemic tissue to oxygen, resulting in the formation of&#xD;
      large amounts of highly reactive oxygen species (ROS) within minutes. ROS lead to oxidative&#xD;
      stress, which causes extensive damage to cell structures and leads to cell death.&#xD;
      Consequently, necrosis and apoptosis are responsible for organ dysfunction and functional&#xD;
      outcome of these patients.&#xD;
&#xD;
      Such injury of neural tissue causes brain damage, which is ultimately responsible for poor&#xD;
      neurological and thus functional outcome of OHCA survivors. The extent of brain damage can be&#xD;
      determined in several ways: clinically by assessing quantitative and qualitative&#xD;
      consciousness and the presence of involuntary movements in an unconscious patient, by&#xD;
      assessing activity on electroencephalographic record, by imaging of the brain with computed&#xD;
      tomography and magnetic resonance imaging, as well as by assessing levels of biological&#xD;
      markers of brain injury. Of the latter, the S-100b protein and neuron-specific enolase have&#xD;
      been shown to be suitable for such assessment.&#xD;
&#xD;
      Oxidative stress is counteracted by the body with endogenous antioxidants that balance excess&#xD;
      free radicals and stabilize cellular function. Vitamin C (ascorbic acid) is the body's main&#xD;
      antioxidant and is primarily consumed during oxidative stress. Large amounts of ROS rapidly&#xD;
      depletes the body's vitamin C stores.&#xD;
&#xD;
      Humans cannot synthesise vitamin C and enteral uptake of vitamin C is limited by transporter&#xD;
      saturation. On the other hand, parenteral (venous) dosing of vitamin C can achieve&#xD;
      concentrations of vitamin C above physiological and thus produce a stronger antioxidant&#xD;
      effect. The beneficial effect of parenteral dosing of vitamin C has been establish in several&#xD;
      preclinical and clinical studies in patients with ischemic stroke and cardiac arrest.&#xD;
&#xD;
      The investigators hypothesize that there is a similarly beneficial effect of vitamin C in&#xD;
      survivors of OHCA.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biomarkers of neurological injury</measure>
    <time_frame>5th day</time_frame>
    <description>Serum levels of protein S-100b and neuron-specific enolase.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brain imaging (CT and MRI)</measure>
    <time_frame>3rd-10th day</time_frame>
    <description>Unconscious survivors will have first brain imaging on the 3rd day, if still unconscious, second imaging around the 10th day. Imaging results will be descriptive (normal or pathological with signs of global ischemic injury: generalised edema, reduced grey and white matter differentiation, obliteration of the sulci). Second image will be compared to the first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electroencephalography (EEG)</measure>
    <time_frame>3rd-10th day</time_frame>
    <description>Unconscious survivors will have first EEG on the 3rd day, if still unconscious, second imaging around the 10th day. EEG results will be descriptive (normal or pathological with background suppression with or without periods of bursts, with or without response to external stimulus and similar patterns). Second EEG will be compared to the first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pupils</measure>
    <time_frame>from admission until 14 days or till discharge from ICU or death (whatever comes first)</time_frame>
    <description>Pupils size, reactivity and symmetry on admission and during hospitalisation will be observed daily.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of involuntary movements</measure>
    <time_frame>from admission until 14 days or till discharge from ICU or death (whatever comes first)</time_frame>
    <description>The presence of involuntary movements will be observed daily.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of GCS</measure>
    <time_frame>from admission until 14 days or till discharge from ICU or death (whatever comes first)</time_frame>
    <description>Level of consciousness will be determined daily with Glasgow Coma Scale (GCS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of FOUR</measure>
    <time_frame>from admission until 14 days or till discharge from ICU or death (whatever comes first)</time_frame>
    <description>Level of consciousness will be determined daily with Full Outline of UnResponsiveness (FOUR) score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral Performance Category</measure>
    <time_frame>from admission till discharge from ICU or death (whatever comes first)</time_frame>
    <description>Cerebral Performance Category (CPC) at discharge will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular ejection fraction</measure>
    <time_frame>from admission until 14 days or till discharge from ICU or death (whatever comes first)</time_frame>
    <description>Left ventricular ejection fraction (first, last, best, worst), determined by ultrasound will be noted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arrhythmias</measure>
    <time_frame>from admission until 14 days or till discharge from ICU or death (whatever comes first)</time_frame>
    <description>Presence of arrhythmias and the need for treating them will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of heart failure</measure>
    <time_frame>from admission until 14 days or till discharge from ICU or death (whatever comes first)</time_frame>
    <description>Clinical evaluation of heart failure according to Killip-Kimball classification will be performed (worst result).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum troponin level</measure>
    <time_frame>from admission until 14 days or till discharge from ICU or death (whatever comes first)</time_frame>
    <description>Serum troponin levels will be determined (on admission, minimal, maximal).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Brain natriuretic peptide</measure>
    <time_frame>from admission until 14 days or till discharge from ICU or death (whatever comes first)</time_frame>
    <description>Serum brain natriuretic peptide levels will be determined (on admission, minimal, maximal).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasopressor and/or inotrope need</measure>
    <time_frame>from admission until 14 days or till discharge from ICU or death (whatever comes first)</time_frame>
    <description>The need for vasopressors and inotropes will be noted, along with the name of the substance, maximal dosage and duration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical ventilation</measure>
    <time_frame>from admission until 14 days or till discharge from ICU or death (whatever comes first)</time_frame>
    <description>Days and hours of mechanical ventilation will be noted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney failure</measure>
    <time_frame>from admission until 14 days or till discharge from ICU or death (whatever comes first)</time_frame>
    <description>The need for renal replacement therapy (and consecutive day of such therapy) will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum urea levels</measure>
    <time_frame>from admission until 14 days or till discharge from ICU or death (whatever comes first)</time_frame>
    <description>Serum levels of urea will be recorded (on admission, minimal, maximal).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum creatinine levels</measure>
    <time_frame>from admission until 14 days or till discharge from ICU or death (whatever comes first)</time_frame>
    <description>Serum creatinine levels will be recorded (on admission, minimal, maximal).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum C-reactive protein levels</measure>
    <time_frame>from admission until 14 days or till discharge from ICU or death (whatever comes first)</time_frame>
    <description>Serum C-reactive protein levels will be determined (on admission, minimal, maximal).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum procalcitonin levels</measure>
    <time_frame>from admission until 14 days or till discharge from ICU or death (whatever comes first)</time_frame>
    <description>Serum procalcitonin levels will be determined (on admission, minimal, maximal).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Heart Arrest, Out-Of-Hospital</condition>
  <condition>Biomarkers</condition>
  <condition>Oxidative Stress</condition>
  <condition>Neurological Injury</condition>
  <arm_group>
    <arm_group_label>Vitamin C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group of patients that will receive vitamin C (ascorbic acid 1,5 g mixed with 0,9 % solution of sodium chloride 100 ml every 12 hours for 4 days intravenously).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group of patients that will receive placebo (0,9 % solution of sodium chloride 100 ml every 12 hours for 4 days intravenously).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin C</intervention_name>
    <description>Ascorbic acid 1,5 g intravenously every 12-hours for 4 consecutive days</description>
    <arm_group_label>Vitamin C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0,9 % solution of sodium chloride 100 ml intravenously every 12-hours for 4 consecutive days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - comatose survivors of out-of-hospital arrest&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with trauma, asphyxia, drowning or electrocution as a cause of cardiac arrest&#xD;
&#xD;
          -  history of oxalate nephropathy or nephrolithiasis, glucose-6-phosphate dehydrogenase&#xD;
             deficiency, and hemochromatosis&#xD;
&#xD;
          -  pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrej Markota, MD, PhD, Assist. Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>University Medical Centre Maribor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrej Markota, MD, PhD, Assist. Prof.</last_name>
    <phone>+38651311519</phone>
    <email>andrej.markota@ukc-mb.si</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Matevž Privšek, MD</last_name>
    <phone>+38640642986</phone>
    <email>matevz.privsek@icloud.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Centre Maribor</name>
      <address>
        <city>Maribor</city>
        <zip>2000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <contact>
      <last_name>Andrej Markota, MD, PhD, Assist. Prof.</last_name>
      <phone>+38651311519</phone>
      <email>andrej.markota@ukc-mb.si</email>
    </contact>
    <contact_backup>
      <last_name>Matevž Privšek, MD</last_name>
      <phone>+38640642986</phone>
      <email>matevz.privsek@icloud.com</email>
    </contact_backup>
    <investigator>
      <last_name>Matevž Privšek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrej Markota, MD, PhD, Assist. Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matej Strnad, MD, PhD, Assoc. Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rok Petrovčič, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <reference>
    <citation>Gräsner JT, Lefering R, Koster RW, Masterson S, Böttiger BW, Herlitz J, Wnent J, Tjelmeland IB, Ortiz FR, Maurer H, Baubin M, Mols P, Hadžibegović I, Ioannides M, Škulec R, Wissenberg M, Salo A, Hubert H, Nikolaou NI, Lóczi G, Svavarsdóttir H, Semeraro F, Wright PJ, Clarens C, Pijls R, Cebula G, Correia VG, Cimpoesu D, Raffay V, Trenkler S, Markota A, Strömsöe A, Burkart R, Perkins GD, Bossaert LL; EuReCa ONE Collaborators. EuReCa ONE-27 Nations, ONE Europe, ONE Registry: A prospective one month analysis of out-of-hospital cardiac arrest outcomes in 27 countries in Europe. Resuscitation. 2016 Aug;105:188-95. doi: 10.1016/j.resuscitation.2016.06.004. Epub 2016 Jun 16. Erratum in: Resuscitation. 2016 Dec;109 :145-146.</citation>
    <PMID>27321577</PMID>
  </reference>
  <reference>
    <citation>Nolan JP, Neumar RW, Adrie C, Aibiki M, Berg RA, Böttiger BW, Callaway C, Clark RS, Geocadin RG, Jauch EC, Kern KB, Laurent I, Longstreth WT, Merchant RM, Morley P, Morrison LJ, Nadkarni V, Peberdy MA, Rivers EP, Rodriguez-Nunez A, Sellke FW, Spaulding C, Sunde K, Hoek TV. Post-cardiac arrest syndrome: epidemiology, pathophysiology, treatment, and prognostication. A Scientific Statement from the International Liaison Committee on Resuscitation; the American Heart Association Emergency Cardiovascular Care Committee; the Council on Cardiovascular Surgery and Anesthesia; the Council on Cardiopulmonary, Perioperative, and Critical Care; the Council on Clinical Cardiology; the Council on Stroke. Resuscitation. 2008 Dec;79(3):350-79. doi: 10.1016/j.resuscitation.2008.09.017. Epub 2008 Oct 28.</citation>
    <PMID>18963350</PMID>
  </reference>
  <reference>
    <citation>Sekhon MS, Ainslie PN, Griesdale DE. Clinical pathophysiology of hypoxic ischemic brain injury after cardiac arrest: a &quot;two-hit&quot; model. Crit Care. 2017 Apr 13;21(1):90. doi: 10.1186/s13054-017-1670-9. Review.</citation>
    <PMID>28403909</PMID>
  </reference>
  <reference>
    <citation>Wijdicks EF, Hijdra A, Young GB, Bassetti CL, Wiebe S; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: prediction of outcome in comatose survivors after cardiopulmonary resuscitation (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006 Jul 25;67(2):203-10. Review.</citation>
    <PMID>16864809</PMID>
  </reference>
  <reference>
    <citation>Calderon LM, Guyette FX, Doshi AA, Callaway CW, Rittenberger JC; Post Cardiac Arrest Service. Combining NSE and S100B with clinical examination findings to predict survival after resuscitation from cardiac arrest. Resuscitation. 2014 Aug;85(8):1025-9. doi: 10.1016/j.resuscitation.2014.04.020. Epub 2014 Apr 30.</citation>
    <PMID>24795283</PMID>
  </reference>
  <reference>
    <citation>Shinozaki K, Oda S, Sadahiro T, Nakamura M, Abe R, Nakada TA, Nomura F, Nakanishi K, Kitamura N, Hirasawa H. Serum S-100B is superior to neuron-specific enolase as an early prognostic biomarker for neurological outcome following cardiopulmonary resuscitation. Resuscitation. 2009 Aug;80(8):870-5. doi: 10.1016/j.resuscitation.2009.05.005. Epub 2009 Jun 17.</citation>
    <PMID>19535196</PMID>
  </reference>
  <reference>
    <citation>Spoelstra-de Man AME, Elbers PWG, Oudemans-van Straaten HM. Making sense of early high-dose intravenous vitamin C in ischemia/reperfusion injury. Crit Care. 2018 Mar 20;22(1):70. doi: 10.1186/s13054-018-1996-y. Review.</citation>
    <PMID>29558975</PMID>
  </reference>
  <reference>
    <citation>Levine M, Padayatty SJ, Espey MG. Vitamin C: a concentration-function approach yields pharmacology and therapeutic discoveries. Adv Nutr. 2011 Mar;2(2):78-88. doi: 10.3945/an.110.000109. Epub 2011 Mar 10. Review.</citation>
    <PMID>22332036</PMID>
  </reference>
  <reference>
    <citation>Tsai MS, Huang CH, Tsai CY, Chen HW, Lee HC, Cheng HJ, Hsu CY, Wang TD, Chang WT, Chen WJ. Ascorbic acid mitigates the myocardial injury after cardiac arrest and electrical shock. Intensive Care Med. 2011 Dec;37(12):2033-40. doi: 10.1007/s00134-011-2362-6. Epub 2011 Sep 28.</citation>
    <PMID>21953354</PMID>
  </reference>
  <reference>
    <citation>Tsai MS, Huang CH, Tsai CY, Chen HW, Cheng HJ, Hsu CY, Chang WT, Chen WJ. Combination of intravenous ascorbic acid administration and hypothermia after resuscitation improves myocardial function and survival in a ventricular fibrillation cardiac arrest model in the rat. Acad Emerg Med. 2014 Mar;21(3):257-65. doi: 10.1111/acem.12335.</citation>
    <PMID>24628750</PMID>
  </reference>
  <reference>
    <citation>Gao F, Yao CL, Gao E, Mo QZ, Yan WL, McLaughlin R, Lopez BL, Christopher TA, Ma XL. Enhancement of glutathione cardioprotection by ascorbic acid in myocardial reperfusion injury. J Pharmacol Exp Ther. 2002 May;301(2):543-50.</citation>
    <PMID>11961055</PMID>
  </reference>
  <reference>
    <citation>Nishinaka Y, Sugiyama S, Yokota M, Saito H, Ozawa T. The effects of a high dose of ascorbate on ischemia-reperfusion-induced mitochondrial dysfunction in canine hearts. Heart Vessels. 1992;7(1):18-23.</citation>
    <PMID>1583008</PMID>
  </reference>
  <reference>
    <citation>Basili S, Tanzilli G, Mangieri E, Raparelli V, Di Santo S, Pignatelli P, Violi F. Intravenous ascorbic acid infusion improves myocardial perfusion grade during elective percutaneous coronary intervention: relationship with oxidative stress markers. JACC Cardiovasc Interv. 2010 Feb;3(2):221-9. doi: 10.1016/j.jcin.2009.10.025.</citation>
    <PMID>20170881</PMID>
  </reference>
  <reference>
    <citation>Dingchao H, Zhiduan Q, Liye H, Xiaodong F. The protective effects of high-dose ascorbic acid on myocardium against reperfusion injury during and after cardiopulmonary bypass. Thorac Cardiovasc Surg. 1994 Oct;42(5):276-8.</citation>
    <PMID>7863489</PMID>
  </reference>
  <reference>
    <citation>Henry PT, Chandy MJ. Effect of ascorbic acid on infarct size in experimental focal cerebral ischaemia and reperfusion in a primate model. Acta Neurochir (Wien). 1998;140(9):977-80.</citation>
    <PMID>9842436</PMID>
  </reference>
  <reference>
    <citation>Huang J, Agus DB, Winfree CJ, Kiss S, Mack WJ, McTaggart RA, Choudhri TF, Kim LJ, Mocco J, Pinsky DJ, Fox WD, Israel RJ, Boyd TA, Golde DW, Connolly ES Jr. Dehydroascorbic acid, a blood-brain barrier transportable form of vitamin C, mediates potent cerebroprotection in experimental stroke. Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11720-4.</citation>
    <PMID>11573006</PMID>
  </reference>
  <reference>
    <citation>Lagowska-Lenard M, Stelmasiak Z, Bartosik-Psujek H. Influence of vitamin C on markers of oxidative stress in the earliest period of ischemic stroke. Pharmacol Rep. 2010 Jul-Aug;62(4):751-6.</citation>
    <PMID>20885017</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 10, 2020</study_first_submitted>
  <study_first_submitted_qc>September 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2020</study_first_posted>
  <last_update_submitted>September 21, 2020</last_update_submitted>
  <last_update_submitted_qc>September 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vitamin C</keyword>
  <keyword>biomarkers</keyword>
  <keyword>brain injury</keyword>
  <keyword>cardiac arrest</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trauma, Nervous System</mesh_term>
    <mesh_term>Heart Arrest</mesh_term>
    <mesh_term>Out-of-Hospital Cardiac Arrest</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

